Cooper Companies Boston Consulting Group Matrix
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
Cooper Companies Bundle
Actionable Strategy Starts Here
Curious where Cooper Companies’ products sit—Stars, Cash Cows, Dogs, or Question Marks? Our BCG Matrix preview gives you the headline view, but the full report maps each product to a quadrant with data-backed reasoning. Buy the complete BCG Matrix for quadrant-by-quadrant strategy, actionable recommendations, and ready-to-use Word and Excel files. It’s the fastest way to decide where to invest, divest, or double down.
Stars
Daily silicone hydrogel dailies (MyDay, clariti 1 day)
Daily silicone hydrogel dailies (MyDay, clariti 1 day) sit in CooperCompanies' BCG Stars: high growth, high share — the sweet spot. Consumers keep trading up to dailies; CooperVision, a top-3 global player, leverages breadth and scale to capture this trend, contributing to CooperCompanies' FY2024 net sales of $1.78 billion. Continued push on retail partnerships, fitters, and direct programs is essential; keep feeding it and these investments keep paying back.
Toric portfolios (Biofinity toric, MyDay toric)
Toric portfolios Biofinity toric and MyDay toric address a growing, harder-to-serve astigmatism segment where Cooper’s extensive SKU range and proprietary fit data enable broad coverage and better first-fit success. Strong practitioner trust drives outsized share and recurring revenue from replacement cycles and loyal fittings. Despite ongoing needs for education and chair time—keeping promotional spend continuous—the incremental returns from high retention and premium pricing justify the investment.
Multifocal dailies
Presbyopia affects over 1 billion people worldwide, and many are shifting to premium options; daily multifocals uniquely combine convenience and superior vision to capture that demand. Cooper’s broad multifocal SKU set and strong ECP fitting support drive higher adoption and reported fitting success, giving it a clear commercial edge. Market growth is brisk with dailies now representing the largest soft‑lens segment, margins remain healthy, and market leadership is within reach—priority: keep investing in awareness and fitting tools.
MiSight myopia management
MiSight is a Stars asset for CooperCompanies: FDA-cleared in 2019 with pivotal 3-year RCT showing ~59% reduction in myopia progression; global myopia is projected to affect ~50% of people by 2050, creating structural growth. Parent-friendly positioning and clinical proof unlock adoption curves, but heavy education, practice enablement and access work are required; potential to become category-defining.
- Clinical proof: ~59% slowing (3-yr RCT)
- Regulatory: FDA clearance 2019
- Go-to-market: education, practice enablement, access
Specialty eye care (scleral/ortho-k platforms)
Cooper’s specialty eye-care (scleral/ortho-k) is a niche but accelerating Stars segment driven by rising myopia interest and complex prescriptions; WHO projects myopia could affect about 50 percent of the world by 2050, reinforcing long-term demand. Cooper’s specialty portfolio and practitioner training foster strong loyalty, though fitting support and training remain resource-hungry. Momentum and clinical adoption argue for continued investment.
- High-growth niche
- Strong practitioner loyalty via training
- Resource-intensive fitting/support
- Strategic priority to sustain momentum
Dailies, torics, multifocals, MiSight drive growth; FY2024 net sales $1.78B
CooperCompanies' Stars: dailies, torics, multifocals, MiSight and specialty lenses drive high-growth, high-share momentum—company FY2024 net sales $1.78 billion; dailies now the largest soft‑lens segment. MiSight: FDA clearance 2019; pivotal RCT ~59% myopia slowing (3 yr). Presbyopia >1B affected; myopia could reach ~50% by 2050—invest in fittings, education, access.
| Product | Evidence | Key Stat |
|---|---|---|
| Dailies | Market leadership | Largest soft‑lens segment |
| MiSight | RCT | ~59% slowing; FDA 2019 |
| Presbyopia | Demographic | >1B affected |
| Myopia | Global trend | ~50% by 2050 |
What is included in the product
Detailed Word Document
BCG Matrix of Cooper Companies: evaluates each product line as Stars, Cash Cows, Question Marks, or Dogs with strategic investment guidance.
Customizable Excel Spreadsheet
One-page Cooper Companies BCG Matrix highlighting cash cows and stars to speed strategic decisions and cut analysis time
Cash Cows
Core monthly spheres (Biofinity)
Core monthly spheres Biofinity function as CooperCompanies cash cows: mature, trusted, ubiquitous product lines delivering reliable volume and strong margins; Biofinity-led lenses supported CooperCompanies' ~$3.2B 2024 revenue run-rate and constituted the majority of contact-lens sales in 2024. Low incremental promo needs and stable distribution keep incremental operating gains flowing straight to cash—maintain market leadership, avoid over-engineering.
Legacy silicone hydrogel monthlies (non-premium tiers)
Legacy silicone hydrogel monthlies (non-premium tiers) benefit from stable 30-day replacement cycles and predictable demand; CooperVision held roughly 10% of the global soft lens market in 2024, making volume and fulfillment key. With price points largely set, operational efficiency beats hype: focus on manufacturing yield and logistics to protect low-margin volume. Minimal marketing, prioritize supply reliability and milk gently while defending major retail and practitioner accounts.
Paragard IUD (CooperSurgical)
Paragard IUD (approved in 1984) is a mature contraceptive brand with durable demand and established physician channels, reducing selling friction and repeat-prescription flows.
OB/GYN disposables and office consumables
OB/GYN disposables and office consumables are classic cash cows for Cooper Companies: recurring, sticky usage in routine procedures with predictable reorder cadence and high gross-to-net clarity; market stability in 2024 shows procedure-driven demand remaining flat-to-up 1–3% year over year. Minimal new-product lift required—focus on service, availability and procurement optimization to keep churn near zero.
- Recurring revenue: procedure-driven, high retention
- Margin clarity: predictable gross-to-net
- Ops focus: procurement programs, inventory availability
- Churn target: near 0 with service-led model
Fertility lab consumables (established accounts)
Fertility lab consumables are embedded in IVF workflows with high switching costs, capturing steady replacement demand even as global IVF cycles hover around 3 million/year (2024); operational excellence, not new features, typically delivers the largest margin gains (100–300 basis points) in established accounts. Protect contracts and harvest predictable cash flow.
- High retention: contract lock-ins
- Steady replace: ~3M cycles/yr (2024)
- Margin lever: ops > R&D
- Strategy: defend contracts, maximize cash
Monthly lenses drive >$3B run-rate; procedure products steady; ops focus on supply & margin
Biofinity and legacy monthlies drove Cooper Companies' cash generation in 2024 (Biofinity-led contact-lens revenue supporting a ~3.2B USD run‑rate; CooperVision ≈10% of global soft-lens market), Paragard and OB/GYN disposables showed stable procedure-driven demand (+1–3% 2024), fertility consumables tied to ~3M IVF cycles/yr. Priorities: supply, contracts, margin via ops.
| Cash Cow | 2024 metric | Focus |
|---|---|---|
| Biofinity | ~3.2B run‑rate | market leadership, supply |
| Legacy monthlies | CooperVision ≈10% market | ops efficiency |
| Paragard | Mature Rx | physician channels |
| OB/GYN disposables | +1–3% yr | availability |
| Fertility consumables | ~3M IVF cycles/yr | contract defense |
Full Transparency, Always
Cooper Companies BCG Matrix
The file you're previewing is the final Cooper Companies BCG Matrix report you'll receive after purchase. No watermarks, no demo content—just the fully formatted, analysis-ready document designed for strategic clarity. Once bought, the exact same file is yours to download, edit, print, or present. Delivered immediately, it’s ready to plug into your planning with zero surprises.
Dogs
Legacy hydrogel monthlies (non-silicone)
Legacy hydrogel monthlies (non-silicone) are low-growth dogs: CooperCompanies reported FY2024 revenue of about $3.2 billion while contact lens mix shifts and price erosion left hydrogel monthlies with mid-single-digit share declines year-over-year. Patient and ECP migration to silicone hydrogels and dailies keeps pressure; margins are near break-even after overhead. Sunset or bundle where it aids retention, otherwise prune.
Low-end private-label lenses in price-war channels
Low-end private-label lenses in price-war channels are commoditized, margin-thin, and loyalty-light, forcing Cooper to compete on pennies rather than differentiated value. These SKUs tie up working capital with limited strategic upside and higher inventory churn. Consider exit or strict SKU rationalization to redeploy capital to higher-margin CooperVision products and clinical innovations.
Non-differentiated surgical instruments (crowded categories)
Me-too surgical hardware in crowded categories is squeezed by group purchasing organizations that account for over 80% of US hospital supply buying, leaving little room to raise prices or craft a differentiated story. Cash-trap dynamics appear as inventory days often run 90–120 days while slow-moving SKUs and limited returnability tie up working capital. Strategy should favor divestiture or consolidation into a few scale winners to restore margins and free cash.
Geographic tail SKUs with regulatory drag
Geographic tail SKUs with regulatory drag consume disproportionate compliance overhead and operational attention for negligible revenue contribution; in 2024 CooperCompanies’ global portfolio showed a clear long tail where small markets drive tiny volumes and heavy local certification costs. They distract ops and sales, are hard to scale and harder to defend; trim and redeploy resources to core regions to improve ROI.
- Tag: low-revenue, high-compliance
- Tag: operational distraction
- Tag: poor scalability
- Tag: redeploy to core regions
Aging office/OR accessories with low utilization
Aging office/OR accessories show low utilization; installed-base inertia masks weak unit economics and CooperCompanies FY2024 revenue was $3.2 billion, where accessory lines contributed low-single-digit percentage of sales and replacement cycles often exceed 5 years, flattening upsell and depressing ASPs while support costs erode margin.
- Installed-base inertia hides weak unit economics
- Replacement cycles stretch, upsell lands flat
- Support costs quietly erode margin
- Time to discontinue or replatform
Trim low-margin SKUs, redeploy to core - FY24 rev 3.2B, double down on high-margin
CooperCompanies FY2024 revenue ~$3.2B; legacy hydrogel monthlies face mid-single-digit share declines as patients shift to silicone/dailies, margins near break-even. Private-label and commoditized SKUs are margin-thin; surgical me-too hardware squeezed by GPOs (>80% US hospital buying) with 90–120 inventory days. Trim, divest, redeploy to core high-margin products.
| Dog type | FY2024 metric | Action |
|---|---|---|
| Hydrogel monthlies | mid- single-digit share decline | sunset/bundle |
| Private-label | margin-thin | SKU rationalize/exit |
Question Marks
Digital fitting/remote care tools
Digital fitting and remote care usage is rising and, per McKinsey, telehealth stabilized around 7% of US outpatient visits by 2024, but Cooper’s share and monetization in this space remain fuzzy. These tools could unlock practitioner efficiency and drive patient/provider lock-in if integrated with Cooper’s device portfolio. Realizing value requires investment in UX, EHR/EMR integrations, and clinical proof points. If adoption sticks, this question mark can graduate rapidly to a star.
Genetic testing and analytics in fertility
Genetic testing and analytics in fertility sit in a high-growth segment—industry estimates show reproductive genetics/PGT markets growing at ~10–12% CAGR into 2030—yet adoption is early, with PGT used in roughly 20–30% of IVF cycles in major markets. Competition is fragmented and guidelines are evolving, creating room for differentiation and outcome claims but requiring heavy capital and clinical validation. Cooper should bet selectively where a data advantage and clinical evidence can drive share and pricing power.
Premium dailies expansion in emerging markets
Market growth for premium daily disposables in emerging markets is strong, driven by rising refractive surgery avoidance and hygiene preferences; Cooper’s market share varies widely by country, from low-penetration positions to competitive mid-market standing. Access, pricing and local distribution or OEM partnerships determine trajectory and uptake. Upfront spend in clinician education, registration and supply-chain setup is non-trivial; scale rapidly or pivot to core tiers to protect margins.
Next-gen minimally invasive gyne solutions
Next-gen minimally invasive gyne solutions show an attractive outcomes story with potential to reduce LOS and complications; CooperCompanies reported fiscal 2024 revenue of ~$1.87B, positioning it to invest selectively. However pipelines are crowded (>30 competing assets in 2024 evaluations) and hospital adoption remains slow (typical 18–24 month cycles), evidence- and KOL-driven.
- Focus: targeted clinical/KOL programs
- Payer clarity: prioritize markets with defined CPT/DRG paths
- Invest where real-world evidence can be generated within 12–18 months
Ortho-k ecosystems and myopia services
Ortho-k is a Question Mark for Cooper: rapid patient interest and a fragmented standards landscape meet uneven practitioner readiness, with global myopia prevalence ~34% in 2024 and projections toward 50% by 2050 driving demand.
Ortho-k could complement MiSight to broaden Cooper’s care stack, but training and supply-chain logistics are choke points; invest in regions with dense fitters or exit if customer acquisition cost remains prohibitive.
- rapid interest
- fragmented standards
- uneven practitioner readiness
- complements MiSight
- training & logistics choke points
- invest where fitters dense / pull back if CAC high
Prioritize reimbursed markets with fast RWE: telehealth, PGT, myopia upside
Digital fitting/telehealth (~7% US outpatient visits by 2024) and PGT (10–12% CAGR to 2030) are high-growth but early for Cooper; premium daily disposables and ortho-k face strong regional upside vs. execution/education costs; next-gen gyn requires heavy evidence spend despite Cooper’s $1.87B FY2024 base. Prioritize markets with clear reimbursement and fast real-world evidence timelines.
| Metric | Value |
|---|---|
| Cooper FY2024 rev | $1.87B |
| Telehealth share (US) | ~7% |
| PGT CAGR | 10–12% |
| Global myopia 2024 | ~34% |